Sigyn Therapeutics, Inc. (SIGY)

Sigyn Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0	0	0	0	0.14
Revenue Growth (YoY)	-	-	-	-	405.58%
Cost of Revenue	0.01	0.01	0	0.01	0.04
Gross Profit	-0.01	-0.01	-0	-0.01	0.11
Selling, General & Admin	1.65	1.49	1.27	0.89	0.63
Research & Development	0.8	0.66	0.73	0.03	0
Other Operating Expenses	0	0	-0.54	0	0
Operating Expenses	2.45	2.15	2.01	0.92	0.63
Operating Income	-2.46	-2.15	-2.01	-0.92	-0.52
Interest Income	0	0	0	0	0
Interest Expense	2.04	0.65	0.4	0.34	0.06
Other Expense / Income	-0.35	0.14	0.6	0	2.74
Pretax Income	-4.15	-2.93	-3	-1.26	-3.31
Income Tax	0	0.78	0.4	0.34	-0.18
Net Income	-4.15	-3.71	-3.4	-1.6	-3.13
Shares Outstanding (Basic)	1	37	36	7	1
Shares Outstanding (Diluted)	1	37	36	7	1
Shares Change	-97.06%	2.75%	395.11%	1256.72%	24.90%
EPS (Basic)	-3.77	-0.10	-0.09	-0.22	-5.78
EPS (Diluted)	-3.77	-0.10	-0.09	-0.22	-5.78
Free Cash Flow	-1.38	-1.83	-1.8	-0.84	-0.14
Free Cash Flow Per Share	-1.26	-0.05	-0.05	-0.11	-0.27
Gross Margin	-	-	-	-	75.12%
Operating Margin	-	-	-	-	-361.39%
Profit Margin	-	-	-	-	-2183.82%
Free Cash Flow Margin	-	-	-	-	-100.25%
EBITDA	-2.45	-2.27	-2.05	-0.91	-0.44
EBITDA Margin	-	-	-	-	-308.84%
Depreciation & Amortization	0.01	0.01	0.02	0.01	0.08
EBIT	-2.46	-2.28	-2.07	-0.92	-0.52
EBIT Margin	-	-	-	-	-361.39%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.